InvestSMART

Entropy Neurodynamics Limited (ASX:ENP)

ALERT: Price-sensitive ASX Announcement for ENP
Current share price for ENP : $0.039 0.004 (11.43%)+
Announcement
Release
4 Aug 2026 9:10AM
Price at Release
$0.035
Full Release
download
Summary
Entropy Neurodynamics Limited has received Human Research Ethics Committee approval for a 72-patient Phase 1b/2a multi-indication basket trial to fast-track the commercialisation of TRP-8803, an intravenously administered psilocin formulation. This world-first study, conducted in collaboration with Swinburne University, evaluates TRP-8803 across eight significant disorders, including Anorexia Nervosa, Body Dysmorphic Disorder, and Treatment-Resistant Depression, among others. The trial aims to assess the safety, tolerability, and preliminary efficacy of TRP-8803 and is designed to expand clinical evidence for its precision-controlled psychedelic therapy platform. Entropy's approach is capital-efficient, leveraging a transdiagnostic strategy to explore multiple indications simultaneously, potentially reducing development risk and accelerating commercialisation. The study's outcomes could unlock significant development, commercial, and partnership opportunities, positioning TRP-8803 as a scalable treatment platform.
Key Points
  • Entropy Neurodynamics has approval for a 72-patient Phase 1b/2a basket trial.
  • The trial evaluates TRP-8803 across eight significant disorders.
  • TRP-8803 is an IV-infused psilocin formulation with precision-controlled dosing.
  • The study includes disorders like Anorexia Nervosa and Treatment-Resistant Depression.
  • The trial is conducted in collaboration with Swinburne University.
  • The study aims to fast-track the commercialisation of TRP-8803.
  • A transdiagnostic approach assesses shared mechanisms across multiple disorders.
  • The study is expected to expand clinical evidence and unlock partnership opportunities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.